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Background: There has been a “rising tide” in mastectomy utilization that can be attributed to more skin-sparing
mastectomies (SSMs) performed concurrently with immediate breast reconstruction. We report our experience of
the first use of SERI® Surgical Scaffold (SERI®; Allergan, Inc.) in 21 cases of direct to implant (DTI) breast reconstruction
after SSM.
Methods: Our retrospective experience, from April 2013 to May 2014, is based on 21 cases of direct to implant (DTI)
breast reconstruction after SSM (9 monolateral 6 bilateral). All the patients were oncological with a preoperative
cancer stage was into 0–2 stage. In order to assess the level of satisfaction with the aesthetical result, on 4–13 months
post-operative patients were asked to complete a questionnaire that evaluated various parameters by means of a Visual
Analogue Scale (V.A.S.).
Results: Over a 13-months period, a total of 15 patients underwent 21 immediate breast reconstructive procedures
with Allergan Natrelle 410 style implants plus SERI® after SSMs. Definitive histological examination give evidence of 5
patients intraductal carcinoma, 6 patients multifocal carcinoma and 4 patients carcinoma in situ. 6 bilateral cases of
direct to implant (DTI) breast reconstruction after SSM had a monolateral oncological treatment and on the
other side a prophylactic treatment. At the end of the short follow up (minimum 6 months) all the patient were
cancer free with an excellent outcome. Complication rate presents just one implant exposure followed by a revised
surgery. At V.A.S. the mean patient satisfaction was 5,77 (good), 4,09 (fair) for sensitivity of the nipple areola complex,
6,33 (good) assessment of implant position, 6,28 (good) self esteem, 5,2 (good) attraction ability, 4,99 (fair) intimate
life, 6,81 (good) overall feelings about breast reconstruction, 6,71 (good) simmetry.
Conclusions: The really encouraging results of our early experience will help surgeons introducing SERI® into their
practice to select appropriate patients for direct-to-implant single-stage immediate breast reconstruction. A larger study
cohort and longer follow-up times are required to identify additional predictors and indications.Introduction
Mastectomy remains a common form of treatment for
breast cancer [1,2]. In addition, there has been a “rising
tide” in mastectomy utilization that can be attributed to
more skin-sparing mastectomies (SSMs) performed con-
currently with immediate breast reconstruction. This rise
may be attributed to better identification of women at
high risk for breast cancer with genetic testing, more re-
fined methods of imaging, and a clearer picture of the
late adverse effects of breast irradiation [1-4]. Immediate
breast reconstruction has proven to be a safe and benefi-
cial treatment for women diagnosed with early-stage* Correspondence: roydevita@roydevita.it
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unless otherwise stated.breast cancer, and offers the benefits of improved body
image, health-related quality of life (HRQOL), and patient
satisfaction [5-12]. For women who have the option of
undergoing breast conserving therapy or mastectomy, the
selection of SSM with immediate reconstruction is pre-
ferred by those who want to avoid radiation and local
recurrence, but do not wish to live with a mastectomy
defect [13].
We report our experience of the first use of SERI® Surgi-
cal Scaffold (SERI®; Allergan, Inc.) in 15 patients, 21 cases
of direct to implant (DTI) breast reconstruction after
SSM. SERI® is the first silk derived bioresorbable scaffold
(SBS), it is devoid of animal or human tissue and it is
properly designed for breast reconstruction. We evaluated
the complication rate, clinical course and postoperativeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients who underwent direct-to-implant breast reconstruc-
tions by using SERI and definitive breast implant.
Material and methods
Our retrospective experience, from April 2013 to May 2014,
is based on 21 cases of direct to implant (DTI) breast recon-
struction after SSM (9 monolateral 6 bilateral). All the
breasts were medium size. All the patients were onco-
logical with a preoperative cancer stage was into 0–2 stage
[14]. The exclusion criteria for the current study were as
follows: 1) a history of undergoing irradiation before and
after reconstruction, 2) a history of undergoing neoadju-
vant chemotherapy as part of breast cancer treatment,
and 3) a history of undergoing reconstructive surgery. All
the patients were submitted to retroareolar ductal extem-
porary histological exam to confirm absence of cancer
involvement of the NAC. So all the subcutaneous mastec-
tomy were SSM [15,16]. Patients were followed up for a
mean period ranging from 6 months to 12 months. Data
on age, body mass index, mastectomy weight, duration of
surgical drainage, cancer stage, presence of comorbidities
including diabetes, hypertension, cardiac disease, and
smoking history were tabulated (Table 1).
We evaluated patients characteristics, the clinical course
and postoperative outcomes based on the following factors:
1) seroma formation, 2) infection, 3) hematoma, 4) skin
flap necrosis, nipple areola complex (NAC) necrosis,
5) capsular contracture (Baker grade III or IV), 6) loss
of implant.
All the surgical incision were located at the infra
mammary fold laterally, SSM were performed by using
Metzenbaun scissors to minimize seroma formation
[9,15]. After SSM, during the same operation, the surgical
technique utilized entailed submuscular dissection of the
pectoralis major muscle, suturing of the SERI® to theTable 1 Patients characteristics
Nr. of patients 15
Nr. of breasts treated 21
Median age (41–62) 51,5
Median B.M.I. kg/m2 (18,8-25,9) 22,3
Nr. Breast cancers stage 0 (Ca. in situ) 4 (26,6%)
Nr. Breast cancers stage 1 (Ca multifocal) 6 (40%)
Nr. Breast cancers stage 2 (Ca Intraductal) 5 (33,3%)
Number of active smokers 3 (14,2%)
Number of diabetes mellitus patients 1 (6,6%)
Number of hypertension patients 1 (6,6%)
Follow-Up months (range) 4-13 (9,5)
Duration of subcutaneous drainage, days 4-8 (6)
Duration of intra-pocket drainage, days 9-18 (13,5)inframammary fold, caudal edge of the pectoralis muscle,
and the serratus anterior muscle laterally with 2–0 Vicryl
interrupted suture, thus enveloping the implant with
SERI® for inferior/lateral pole coverage. Two drains,
one above the pectoralis major muscle and one in the
pocket, were used on all patients. So the implant was
inserted into the newly created submuscular pocket.
The implant was covered superiorly with the pectoralis
muscle and inferolaterally with a SERI® sling without
arising serratus muscle and fascia. Prophylactic intra-
venous 2 gr Cefazolin antibiotic use and intraoperative
antibiotic irrigation with riphampicine solution for im-
plants was recorded for all patients. Daily antibiotic
administration was in state untill drainges removed.
All patients were discharged with 2 days hospitalization.
Drains were removed when their output was <30 cc per
24 h for at least 2 consecutive days.
Moreover, in order to assess the level of satisfaction with
the aesthetical result, on 6–13 months post-operatively, pa-
tients were asked without prior notice to complete a ques-
tionnaire that evaluated various parameters (Sensitivity of
the NAC, Assessment of implant position, Self esteem,
Attraction ability, Intimate life, Overall feelings about
breast reconstruction, simmetry) by means of a Visual
Analogue Scale (V.A.S.) [17]. Patients were instructed
to use a numerical scale of 1 to 10, with one as the
worst outcome and 10 as the best possible outcome
(<5 = fair, 5 to 6.9 = good, and ≥7 = very good).
This study was approved by the Regina Elena National
Cancer Institute review board and followed the principles of
the Declaration of Helsinki and subsequent amendments.
All participants provided written informed consent
before participating in the study.
Results
Over a 13-months period, a total of 15 patients underwent
21 immediate breast reconstructive procedures with Aller-
gan Natrelle 410 style implants assisted by SERI® for infer-
ior/lateral pole coverage. Definitive histological examination
give evidence of 5 patients intraductal carcinoma, 6 patients
multifocal carcinoma and 4 patients carcinoma in situ.
6 bilateral cases of direct to implant (DTI) breast re-
construction after SSM had a monolateral oncological
treatment and on the other side a prophylactic treat-
ment [18]. At the end of the short follow up (minimum
4 months) all the patient were cancer free. Definitive
implants in monolateral DTI breast reconstruction
were: FF 375 (3) - 425 (1) - FF 475 (1), MF 335 (1) -
375 (2), LF 310 (1); two of nine monolaeral breast re-
construction needed contralateral breast reshaping by
mastopexy to improve simmetry. 6 bilateral DTI breast
reconstruction were performed by using FF 375 (1 pt)-
425 (1 pt), MF 420 (3 pts), MF 375 (1 pt). The Senior
Author performed both procedures, SSM and reconstructive
Table 3 Visual Analogue Scale (VAS) administered to
patients at 6–13 months follow-up. Mean, range of
15 patients
Patients parameter evaluation Satisfaction rate
Sensitivity of the nipple areola complex 4,09 (fair)
Assessment of implant position 6,33 (good)
Self esteem 6,28 (good)
Attraction ability 5,2 (good)
Intimate life 4,99 (fair)
Overall feelings about breast reconstruction 6,81 (good)
Simmetry 6,71 (good)
Mean patient satisfaction 5,77 (good)
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Department, using a standardized technique, above de-
scribed, for subcutaneous mastectomy and DTI breast
reconstruction with SERI® as a pectoral extender. The
Senior Author performed as well the contralateral masto-
pexy in 2 cases as breast simmetrization. The encouraging
preliminary results are showed in Table 2. Regarding the
unique case of partial flap necrosis (4,7%), in an active
smoker, monolateral breast reconstruction and subse-
quent implant exposure, the Senior Author performed a
latissimus dorsi flap with implant substitution (Allergan
Natrelle 410 Style FF 290) as a salvage with an excellent
outcome.
The mean patient satisfaction was 5,77 (good), 4,09 (fair)
for sensitivity of the nipple areola complex, 6,33 (good)
assessment of implant position, 6,28 (good) self esteem,
5,2 (good) attraction ability, 4,99 (fair) intimate life,
6,81 (good) overall feelings about breast reconstruc-
tion, 6,71 (good) simmetry (Table 3) (Figures 1, 2 and 3).
Discussion
Traditional prosthetic breast reconstruction consisting of
a two-stage tissue expander-implant procedure is the most
widely practiced technique in postmastectomy breast re-
construction. Disadvantages of this technique include two
operations, multiple office visits for expansion, pain after
expansion, and significant capsular adjustment at the time
of implant exchange. Despite these disadvantages, this
technique is safe and predictable and allows for good aes-
thetic results [19,20]. Acellular dermal matrices were
introduced into clinical practice to aid in a variety of
surgical problems, including complex abdominal wall
reconstruction [21], facial paralysis [22], and dural
defects [23]. In 2001, Duncan reported the first use of
acellular dermal matrix in breast surgery to correct
persistent implant rippling in both aesthetic and recon-
structive cases [24]. In 2006, Salzberg reported experience
using acellular dermal matrix to achieve a single-stage im-
plant reconstruction with full implant coverage [25]. Since
then, various types of tissue products have been developed
for two stages and direct to implant breast reconstructionTable 2 Results
Nr. Seroma formation self-limiting 1 (4,7%)
Nr. Late Seroma formation 0 (0%)
Infection 0 (0%)
Hematoma self-limiting 1 (4,7%)
Hematoma requiring surgical revision 0 (0%)
Partial skin flap necrosis 1 (4,7%)
NAC necrosis 0 (0%)
Capsular contracture 0 (0%)
Loss of implant 1 (4,7%)and these include AlloDerm (LifeCell Corp.), Strattice
(LifeCell Corp.), DermaMatrix (Synthes Inc., West Chester,
PA, USA), FlexHD (Ethicon Inc., Somerville, NJ, USA),
and Permacol (Covidien, Mansfield, MA, USA) [25,26]. In
addition, these products vary in many ways, depending on
the source of tissue material, manufacturing methods, stor-
age and surgical preparation, available size, and cost. How-
ever, their use is often limited due to the lack of outcome
data [26,27]. Moreover the most recent major retrospective
studies have demonstrated an high rates of complications
such as infection, seroma formation, capsular contracture,
implant exposure that needs reoperation with the above
matrices.
In April 2013 Allergan presents and launches SERI® in
the European and US market. It is the first silk derived
bioresorbable scaffold (SBS) properly designed for breast
reconstruction, BIOSILK™ is devoid of animal or human
tissue. It is biocompatible which allows interaction with
the body, it is bioresorbed by enzymatic and cellular di-
gestion. Native tissue generation occurs in its place and
bioresorption is expected within 18–24 months.
The porous design of SERI® allows for rapid neovascu-
larisation and growth of functional tissue, gradual transfer
from SERI® to new and well vascularised tissue provides
consistent and predictable support in direct to implant
single stage breast reconstruction.
BIOSILK™ purification removes impurities leaving an
ultrapure bioprotein designed to provide an improved
and consistent user experience. Operatively SERI® can be
cut without unravelling, is easy to suture (large pores),
does not require refrigeration or rehydration as the sur-
gical ADM scaffold previously described [27,28]. Our ex-
perience reported start on April 2013 until May 2014, it
is based on 21 cases of direct to implant (DTI) breast re-
construction after SSM (9 monolateral 6 bilateral) by
using SERI as surgical scaffold to envelope the implant
for inferior/lateral pole coverage. We had strictly re-
stricted surgical incications in our series patients. All
the breasts were medium size. All the patients were
Figure 1 Case 1. A: 39 YO nulliparous, preoperative view, grade 1 intraductal carcinoma on the right breast. B: Right breast: therapeutic nipple
skin sparing mastectomy direct to implant Allergan 410 Style FF 425 and SERI®. 3 weeks postop. C: 5 months postop.
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[15]. The patients enrolled doesn’t has a history of
undergoing irradiation before and after reconstruction
and neoadjuvant chemotherapy as part of breast can-
cer treatment.
Direct-to-implant single-stage immediate breast recon-
struction has gained significant popularity as an elegant
single-stage solution to postmastectomy prosthetic breast
reconstruction [29-31]. In addition to completing breast
reconstruction in a single stage, the benefits of SERI® in-
clude improved control of the breast pocket, augmenta-
tion of soft-tissue coverage in the lower pole, and a
postulated decrease in capsular contracture [32-34]. In
Litterature, one of the most common reasons for early re-
vision in the direct-to-implant single-stage immediate
breast reconstruction group is Baker grade III- IV capsular
contracture (mean 34.6 percent of failed single-stage) [14].
Despite the postulated hypothesis that SERI® may prevent or
alleviate capsular contracture, confirmed by our results, cap-
sular contracture still remains one of the most likely causes
for revision; so we need a further follow up to declare that
DTI breast reconstruction by using SERI® and definitive im-
plant present a low rate of capsular contracture.
Single-stage prosthetic breast reconstruction using sur-
gical scaffold has widespread implications for patients and
the health care system. Knowing the expense of surgical
scaffold, cost analysis at our Institution showed that breast
reconstruction with SERI® was cost effective compared
with traditional two-stage reconstruction when performedFigure 2 Case 2. A: 45 YO, preoperative view, previous quadrantectomy
carcinoma on the left breast. B: Left breast: therapeutic nipple skin spari
SERI®. 2 weeks postop. Right breast: prophylactic nipple skin sparing ma
2 weeks postop. C: 4 months postop.in a single stage [35]. It has the potential to decrease surgi-
cal morbidity, surgical wait times, and operative costs.
Moreover, it is important to accurately identify patients
who are likely to have successful outcomes following
direct-to-implant single-stage immediate breast recon-
struction. An intraoperative algorithm based on flap thick-
ness and quality of skin has been suggested to guide use
of this technique [36]. It has also been advised that imme-
diate implant-based reconstruction with or without the
use of surgical scaffolds should be used with caution in
large, ptotic breasts and in patients with a history of ir-
radiation or chemotherapy [37]. Preoperative patient se-
lection criteria specific to direct-to-implant single-stage
immediate breast reconstruction using surgical scaffold do
not exist in the Literature [25,26]; so our experience was
to used the basic principle of reasoning: small, medium
breasts leaving out potential risk factors such as Radiother-
apy and Chemoterapy or heavy levels of comorbidities.
Thus, in this study, we analyzed our direct-to-implant
single-stage immediate cohort and found that patients
with small, medium breasts (A cup, 300-g mean mastec-
tomy weight) were less likely to require an early surgical
revision compared with Litterature data. Our guidelines
allows us a 0% complication rates of infection, seroma,
hematoma, and capsular contracture as well.
Our early breast revision rate in direct-to-implant
single-stage immediate breast reconstruction patients
was 4,7 percent (one case), which is slightly lower than
the revision rate of 28.6 percent recently reported in awithout Radiotherapy on the right breast, grade 1 multifocal
ng mastectomy direct to implant Allergan 410 Style MF 420 and
stectomy direct to implant Allergan 410 Style MF 420 and SERI®.
Figure 3 Case 3. A: 51 YO, preoperative view, previous biopsy grade 2 intraductal carcinoma on the left breast. B: Therapeutic nipple skin
sparing mastectomy direct to implant Allergan 410 Style MF 375 and SERI®. 3 weeks postop, initial skin suffering. C: 2 months postop implant and
SERI® exposure before reoperation. D: 7 months postop after implant explantation and Latissimus dorsi miocutaneous flap as a salvage procedure
with Allergan 410 MF 335.
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reconstruction series by Roostaeian [38]. In the largest
series by Salzberg et al., an overall revision rate of 19.1
percent can be deduced by combining elective revi-
sions (15.2 percent) with revisions resulting from com-
plications (3.9 percent) [39]. Given that, this cohort
represents our early experience using SERI®, our lower
early revision rate may be attributable to the restric-
tion of indications associated with this technique.
The main limitation of our study is the small cohort size
and the absence of breasts with postoperative irradiation.
Comparing our results with Gdalevitch experience [25,26],
irradiation was not found to be statistically different be-
tween the successful and failed single-stage groups, likely
because of the small number of irradiated patients in his
cohort [32 breasts (18.9 percent)]. In a larger group of
patients, widening the indications, we would expect
preoperative/postoperative irradiation to be statistically
significant as predictors of single-stage potential failure re-
lated, by using SERI®, on radiotherapy as well.
We are aware about our preliminary report considering
small population and short follow up. We will continue to
follow up our direct-to-implant single-stage immediate
breast reconstruction cohort by using SERI®, for long-term
revision rates to be sure about definitive results with this
new surgical scaffold.
Conclusions
Direct-to-implant single-stage immediate breast recon-
struction offers many advantages to both patients andthe health care system. Correctly identifying patients
most likely to have a successful outcome in a single
stage will allow health care providers to better allocate
health care resources. In this study, we present our early
experience with direct-to-implant single-stage immediate
breast reconstruction by using SERI®. Patients with
smaller, medium breasts had successful single-stage out-
comes. The really encouraging results of our early experi-
ence will help surgeons introducing SERI® into their
practice to select appropriate patients for direct-to-implant
single-stage immediate breast reconstruction. In summary,
the use of SERI® in implant-based reconstruction appears
to be effective. A larger study cohort and longer follow-up
times are required to identify additional predictors and
indications.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
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